Cancer is one of the most devastating diseases that afflict humans, and its treatment has always been a challenge for medical professionals. However, with continuous research and development in the field of medicine, new drugs are being discovered to fight against cancer. One such drug that shows great promise is Dasatinib. It works by inhibiting specific enzymes that promote cancer cell growth and multiplication, thereby stopping or slowing down the spread of cancers such as chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). In this blog post, we will take a closer look at how Dasatinib works, its side effects, and how it is administered to patients undergoing cancer treatment.
Dasatinib is a highly effective drug that belongs to the class of tyrosine kinase inhibitors (TKIs). It works by selectively inhibiting specific enzymes that promote cancer cell growth and multiplication. The drug blocks the activity of two important proteins, known as BCR-ABL and SRC kinases, which are often found in abnormal levels in people suffering from leukemia.
BCR-ABL plays a crucial role in the development of CML, while SRC kinases contribute to resistance against chemotherapy. By blocking these enzymes, Dasatinib interrupts key signaling pathways within cancer cells, leading to their death or slowdown in growth.
Interestingly, Dasatinib has also been shown to have other therapeutic uses beyond cancer treatment. For example, it has been used experimentally for treating some autoimmune conditions such as rheumatoid arthritis due to its ability to suppress certain immune system components.
Dasatinib's effectiveness has made it an essential weapon in fighting against several types of cancers and improving disease outcome for many patients who would otherwise have limited options for treatment.
Dasatinib, like any other cancer medication, has its fair share of side effects. Some of these side effects are mild and short-lived; others can be severe and long-lasting. It's important to note that not all patients experience the same side effects with Dasatinib.
Commonly reported side effects include nausea, vomiting, diarrhea, abdominal pain, headache, fatigue and muscle pain. These symptoms usually subside after a few days or weeks.
Some patients may also experience fluid retention in their legs and feet as well as swelling around the eyes. This is due to the drug's ability to block certain proteins involved in regulating fluids in the body.
Other potential side effects of Dasatinib include respiratory infections such as pneumonia or bronchitis due to its effect on white blood cells responsible for fighting infections. Additionally, some patients may develop skin rashes or changes in hair color during treatment with Dasatinib.
Dasatinib is an oral medication that is usually taken once a day, with or without food. The tablets should be swallowed whole and not crushed or chewed. It's important to take Dasatinib at the same time each day, so it becomes part of your daily routine.
The dose of Dasatinib depends on several factors such as body weight, medical condition and response to treatment.
Dasatinib is a promising drug for the treatment of cancer. Its unique mechanism of action and ability to target multiple proteins make it an effective option for patients with different types of cancers. Although there are potential side effects associated with its use, they can be managed through proper monitoring and medical care.
As medical professionals, it is important to stay updated on the latest developments in cancer treatment options like Dasatinib. By understanding how this drug works and its potential benefits and risks, we can provide our patients with the best possible care and help them achieve better outcomes in their fight against cancer.
1.
Three Cycles of Chemo Noninferior to Six for Rare Childhood Eye Cancer
2.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
3.
What Dolph Lundgren's journey from terminal diagnosis to 'cancer free' can tell us about cancer care
4.
Experts Discuss Groundbreaking Advances in EGFR-Mutant Lung Cancer
5.
Analysis of 2021 data shows new cancer diagnoses did not rebound as expected following pandemic
1.
Biologic Therapies for Cutaneous Immune-Related Adverse Events in the Era of Immune Checkpoint Inhibitors
2.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
3.
The Importance of Early Detection in Skin Cancer: Why Regular Skin Exams Matter
4.
The Growing Challenge of Haematological Malignancies in Older Adults
5.
Landmark Medical Oncology Trials Redefining Early Breast Cancer Management
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
4.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation